Article Correctness Is Author's Responsibility: FDA: Risk of Severe Increase in Disability Following MS Treatment Discontinuation

The article below may contain offensive and/or incorrect content.

From September 2010 to February 2018, the FDA has identified 35 cases of severe increased disability accompanied by the presence of new lesions on MRI that occurred 2 to 24 weeks after stopping treatment with fingolimod.